# Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

> **NCT00002535** · PHASE2 · COMPLETED · sponsor: **St. Luke's Medical Center**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** lymphokine-activated killer cells
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **DRUG:** cyclophosphamide
- **DRUG:** indomethacin

## Key facts

- **NCT ID:** NCT00002535
- **Lead sponsor:** St. Luke's Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-07
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002535, "Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*